Trends in psoriatic arthritis epidemiology in Poland

Tłustochowicz, Małgorzata; Wierzba, Waldemar; Marczak, Michał; Tłustochowicz, Witold; Śliwczyński, Andrzej; Raciborski, Filip; Kwiatkowska, Brygida; Brzozowska, Melania; Jacyna, Andrzej; Kisiel, Bartłomiej

doi:10.1007/s00296-020-04734-x

Cited by 5 publications

(3 citation statements)

References 21 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may imply a pressing concern of potential underdiagnosis and underscores the imperative for early detection in clinical practice. Tłustochowicz et al described in recent years a gradual rise in psoriatic arthritis detection, which confirms our observations [34].…”

Section: Discussionsupporting

confidence: 93%

An Observational Study of 147 Psoriasis Patients: Overweightness and Obesity as a Significant Clinical Factors Correlated with Psoriasis

Czarnecka,

Zabłotna,

Purzycka-Bohdan

et al. 2023

Medicina

View full text Add to dashboard Cite

Background and Objectives: Psoriasis is a common, chronic, and immune-mediated inflammatory skin disease recognized to lead to a wide range of comorbid disorders, mainly obesity. The study aimed to evaluate the problem of overweightness and obesity among psoriasis patients in the context of their prevalence and influence on the disease course. Materials and Methods: The study group encompassed 147 adult patients with plaque psoriasis. Results: The prevalences of overweightness (39.46%) and obesity (37.41%) demonstrated in the study showed the strong predisposition of psoriatic patients for abnormal body mass. The vast majority (77%) of subjects with psoriatic arthritis were overweight or obese. The results of the correlation analysis revealed the significant impacts of overweightness and obesity, as defined by the BMI index, on modifying the severity of psoriasis (as assessed by the PASI with a correlation coefficient of R = 0.23, p = 0.016; and BSA values with a correlation coefficient of R = 0.21, p = 0.023), particularly in contrast to patients with a normal body mass. Conclusions: Overweightness and obesity constitute a major health burden among psoriatic patients, influencing the disease course and severity. Enhanced understanding of the phenomenon may directly translate into improving disease management and overall patient care.

show abstract

Section: Discussionsupporting

confidence: 93%

An Observational Study of 147 Psoriasis Patients: Overweightness and Obesity as a Significant Clinical Factors Correlated with Psoriasis

Czarnecka,

Zabłotna,

Purzycka-Bohdan

et al. 2023

Medicina

View full text Add to dashboard Cite

show abstract

“…Our study revealed an unsettling phenomenon of a considerable number of articular complaints (almost half of the study group) among polish psoriatic patients. The investigation of the National Health Fund (NHF) of psoriatic arthritis (PsA) epidemiology in Poland pinpointed increasing prevalence of the disorder in the recent decade (nowadays 73.11 cases per 100,000) [ 22 , 23 ]. Alinaghi’s et al meta-analysis showed that those data are relatable to populations of European ancestry suffering from psoriasis (PsA prevalence equal to 22.7%) [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

Chronic Plaque Psoriasis in Poland: Disease Severity, Prevalence of Comorbidities, and Quality of Life

Purzycka-Bohdan

Kisielnicka

Zabłotna

et al. 2022

JCM

View full text Add to dashboard Cite

The epidemiology of psoriasis has not been widely assessed in Polish population so far. This study aimed to investigate psoriasis epidemiological situation by evaluating disease course and severity, management, comorbidities, environmental factors, and knowledge about this disorder among psoriatic patients in Poland. A cross-sectional cohort population-based study enrolled 1080 psoriatic patients and 1200 controls. The mean age of psoriasis onset was 27.6 years; 78.24% had type I psoriasis. Positive family history of psoriasis was reported in 44.81% of patients, whereas itch was reported in vast majority of patients (83.33%). Based on PASI score moderate psoriasis was the most common in studied group (mean 12.63 ± 9.33, range 0–67.2). The DLQI score (12.01 ± 7.41, range 0–30.0) indicated a very large effect of psoriasis on the quality of life. Hypertension was the most prevalent comorbidity (33.80%), followed by obesity (16.85%) and dyslipidemia (11.85%). Stress was the foremost cause of disease exacerbation (66.20%); however, infections (44.07%) and seasonal changes (45.09%) had also an impact on the course of psoriasis. Psoriatic patients were more often smokers (37.59%) vs. general population (27.50%; p < 0.0001). In conclusion, epidemiological studies help clinicians in better disease and patient understanding, which may translate into better management and patient compliance.

show abstract

“…The present study is also limited by lack of a comparator cohort for other biologics, which makes it difficult to benchmark measures of effectiveness and safety. It should be noted that there is a steady increase in the recorded prevalence of PsA in Poland [ 44 , 45 ], while the current treatment armamentarium remains limited. More data are necessary to support the decisions of providers and policy makers to enable reimbursement of novel and effective therapies.…”

Section: Discussionmentioning

confidence: 99%

Drug Retention and Safety of Secukinumab in a Real-World Cohort of Ankylosing Spondylitis and Psoriatic Arthritis Patients

Moskal

Krawiec

Zaręba³

et al. 2022

IJERPH

View full text Add to dashboard Cite

Real-life data that support effectiveness of secukinumab (SEC), an interleukin 17A inhibitor, in Poland are few. We aimed to evaluate SEC effectiveness based on drug retention and safety measures reported in electronic medical records (EMRs) of patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) from two tertiary-care centers in the region of Lesser Poland. A total one-hundred eighty seven (127 PsA and 60 AS) first (n = 112), second (n = 59) and third-line SEC users were enrolled. The mean (SD) age of the sample was 45.7 (12.9), and 48% were male. All patients were classified with active and severe disease prior to initiation. Administrative delays for SEC users last a median 2 weeks. Median delay from symptom onset to diagnosis was 4 years (IQR 8), and differed by predominant disease subtype. The inefficacy rate was 10.7% and 18.6% for first and second-line users with median (IQR) drug maintenance estimated at 1.22 years (1.46) and 1.51 (1.38), respectively. First-year drug loss defined as drug switch due to inefficacy or adverse event was rare, with median estimates of 0.91 (95% CI; 0.85, 0.97) and 0.86 (95% CI; 0.77, 0.95) for first and second-line, respectively.

show abstract

Trends in psoriatic arthritis epidemiology in Poland

Cited by 5 publications

References 21 publications

An Observational Study of 147 Psoriasis Patients: Overweightness and Obesity as a Significant Clinical Factors Correlated with Psoriasis

An Observational Study of 147 Psoriasis Patients: Overweightness and Obesity as a Significant Clinical Factors Correlated with Psoriasis

Chronic Plaque Psoriasis in Poland: Disease Severity, Prevalence of Comorbidities, and Quality of Life

Drug Retention and Safety of Secukinumab in a Real-World Cohort of Ankylosing Spondylitis and Psoriatic Arthritis Patients

Contact Info

Product

Resources

About